Advertisement

Topics

PubMed Journals Articles About "Brief Title: Study To Determine Effectiveness Of GSK1120212 In BRAF Mutation-positive Melanoma Subjects Previously Treated With Or Without A BRAF Inhibitor" RSS

17:01 EDT 21st May 2018 | BioPortfolio

Brief Title: Study To Determine Effectiveness Of GSK1120212 In BRAF Mutation-positive Melanoma Subjects Previously Treated With Or Without A BRAF Inhibitor PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Brief Title: Study To Determine Effectiveness Of GSK1120212 In BRAF Mutation-positive Melanoma Subjects Previously Treated With Or Without A BRAF Inhibitor articles that have been published worldwide.

More Information about "Brief Title: Study To Determine Effectiveness Of GSK1120212 In BRAF Mutation-positive Melanoma Subjects Previously Treated With Or Without A BRAF Inhibitor" on BioPortfolio

We have published hundreds of Brief Title: Study To Determine Effectiveness Of GSK1120212 In BRAF Mutation-positive Melanoma Subjects Previously Treated With Or Without A BRAF Inhibitor news stories on BioPortfolio along with dozens of Brief Title: Study To Determine Effectiveness Of GSK1120212 In BRAF Mutation-positive Melanoma Subjects Previously Treated With Or Without A BRAF Inhibitor Clinical Trials and PubMed Articles about Brief Title: Study To Determine Effectiveness Of GSK1120212 In BRAF Mutation-positive Melanoma Subjects Previously Treated With Or Without A BRAF Inhibitor for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Brief Title: Study To Determine Effectiveness Of GSK1120212 In BRAF Mutation-positive Melanoma Subjects Previously Treated With Or Without A BRAF Inhibitor Companies in our database. You can also find out about relevant Brief Title: Study To Determine Effectiveness Of GSK1120212 In BRAF Mutation-positive Melanoma Subjects Previously Treated With Or Without A BRAF Inhibitor Drugs and Medications on this site too.

Showing "Brief Title Study Determine Effectiveness GSK1120212 BRAF Mutation" PubMed Articles 1–25 of 68,000+

Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.

The major aim of this study was to evaluate the performance of anti-BRAF V600E (VE1) antibody in colorectal tumors with and without KRAS mutation. KRAS and BRAF are two major oncogenic drivers of colorectal cancer (CRC) that have been frequently described as mutually exclusive, thus the BRAF V600E mutation is not expected to be present in the cases with KRAS mutation. In addition, a review of 25 studies comparing immunohistochemistry (IHC) using the anti-BRAF V600E (VE1) antibody with BRAF V600E molecular t...


Improving classification of melanocytic nevi: BRAF V600E expression associated with distinct histomorphologic features.

A subset of melanomas carrying a BRAF V600E mutation, the most common targetable mutation in melanoma, arises in association with a melanocytic nevus also harboring a BRAF V600E mutation. The detailed histomorphologic characteristics of BRAF V600E-positive nevi are not systematically documented.

Concordance of somatic mutational profile in multiple primary melanomas.

This study aimed to determine the frequency and concordance of BRAF and NRAS mutation in tumours arising in patients with multiple primary melanoma (MPM). Patients with MPM managed at one of three tertiary referral centres in Melbourne, Australia from 2010-2015 were included. Incident and subsequent melanomas underwent mutation testing. Cohen's kappa (κ) coefficient assessed agreement between incident and subsequent primary melanomas for both BRAF and NRAS mutation status (mutant vs. wild-type). Mutation t...


Haddad syndrome novel association with BRAF mutation.

This is a report of a 36 week male infant who suffered abdominal distension and difficulty opening bowels within first few days of life and showed a pattern of hypoventilation and apnea associated with sleep. His diagnostic studies confirmed the diagnosis of congenital central hypoventilation syndrome CCHS (PHOX2B mutation) and Hirschsprung's disease and later found a further mutation of BRAF oncogene. This describes a novel association between these mutations and the shared qualities of tumorigenesis betwe...

A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.

Treatment for patients with V600 mutation of the B-Raf protooncogene BRAF (BRAF-V600) and metastatic stage IV or unresectable stage III melanoma has greatly advanced with the introduction of selective BRAF inhibitors (BRAFi), such as vemurafenib and dabrafenib, combined with mitogen-activated protein kinase kinase inhibitors (MEKi), such as cobimetinib and trametinib, as first-line therapy [1,2]. Two mutations, V600E and V600K, are routinely searched in patients with stage IV and unresectable stage III canc...

BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and Mutation-specific Immunohistochemistry.

The B-Raf proto-oncogene (BRAF) encodes a cytoplasmic serine/threonine kinase with a key role in regulating the mitogen-activated protein kinase signal transduction pathway. An activating missense mutation in codon 600 of exon 15 (V600E) of BRAF gene has been identified in multiple neoplasms including melanoma, colorectal carcinoma, papillary thyroid carcinoma, hairy cell leukemia, and Langerhans cell histiocytosis. Patients with BRAF V600E-mutated melanoma respond to FDA-approved BRAF inhibitors. In additi...

BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report.

BRAF signaling is involved in melanoma growth in more than half of metastatic patients. In the last few years, new drugs that block this pathway have significantly improved the outcomes of patients with metastatic melanoma. Ninety percent of BRAF mutations involve exon 15, and the most frequent, V600E, results from the amino acid change from valine (V) to glutamic acid (E). BRAF inhibitor treatments have shown a notable overall response rate and improvements in progression-free and overall survival. Rare BR...

Current insights of BRAF inhibitors in cancer.

Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large number of human tumors. FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clinical responses extending survival of melanoma patients. However, these drugs display paradoxical activation in normal tissue with BRAFWT due to RAF transactivation and priming, acquired drug resistance, and limited clinical effectiveness in non-V600 BRAF-dependent tumors, underscoring the urgent need to develop improved BRAF inhibitor...

A sibling pair with cardiofaciocutaneous syndrome (CFC) secondary to BRAF mutation with unaffected parents-the first cases of gonadal mosaicism in CFC?

Cardiofaciocutaneous (CFC) syndrome is a RASopathy characterized by intellectual disability, congenital heart defects, a characteristic facial appearance, gastro-intestinal complications, ectodermal abnormalities and growth failure. The RASopathies result from germline mutations in the Ras/Mitogen-activated-protein-kinase (MAPK) pathway. CFC is associated with mutations in BRAF, KRAS, MEK1 and MEK2. CFC has been considered a "sporadic" disorder, with minimal recurrence risk to siblings. In recent years, ver...

Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer.

Purpose For the past 65 years, patient age at diagnosis has been widely used as a major mortality risk factor in the risk stratification of papillary thyroid cancer (PTC), but whether this is generally applicable, particularly in patients with different BRAF genetic backgrounds, is unclear. The current study was designed to test whether patient age at diagnosis is a major mortality risk factor. Patients and Methods We conducted a comparative study of the relationship between patient age at diagnosis and PTC...

Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.

BRAF mutational testing has become a common practice in the diagnostic process of patients with advanced melanoma. Although time-consuming, DNA sequencing techniques are the current gold standard for mutational testing. However, in certain clinical situations, a rapid test result is required. In this study, the performance of three rapid BRAF mutation tests was compared. Thirty-nine formalin-fixed paraffin-embedded melanoma tissue samples collected between 2007 and 2014 at a single center were included. The...

BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.

BRAF and MEK inhibitors have improved clinical outcomes in advanced, BRAF(V)(600) - mutated melanomas. Acquired resistance occurs in most patients, with numerous and diverse drivers. We obtained pre-treatment and progression biopsies from a patient who progressed on dabrafenib and trametinib. In addition to a preserved BRAF(V)(600E) mutation, an internal deletion (rearrangement) of BRAF was observed in the progression sample. This deletion involved exons 2-8, which includes the Ras-binding domain, and is an...

BRAF-mutant colorectal cancer, a different breed evolving.

BRAF mutant colorectal cancer (BRAF MT CRC) is a unique category of colorectal tumour with peculiar molecular, pathological and clinical features and poor prognosis; despite recent research, BRAF mutation predictive value and standard treatment of BRAF MT CRC still have to be defined. In this review, we focused on this challenging topic. Areas Covered: The potential use of BRAF mutational status among recent additional prognostic and predictive indicators and current treatment strategy in use in these patie...

High incidence of BRAF V600 mutation in Indian patients with head and neck cancer.

In cancer cells, is frequently mutated at codon 600 () leading to the replacement of valine amino acid with other amino acids. The current study was performed to assess the prevalence of  mutation in Indian patients with head and neck squamous cell carcinoma (HNSCC). Among the patients, 27% were homozygous, and 71% were heterozygous for the mutation and only 2% showed a wild genotype. Since identification of  mutation in cancer patients is used for selection of the therapeutic agents, th...

The Role of Title IX Coordinators on College and University Campuses.

The purpose of this study was to better understand the role of Title IX coordinators and their policies across four-year universities and two-year community colleges in the United States (U.S.). There is little information regarding Title IX coordinators' training, background, and policies on how they handle Title IX investigations regarding sexual violence. The data come from an online survey that included 692 Title IX coordinators across four-year (private and public) and two-year campuses and represented...

Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review.

Recent years have brought major advances in the treatment of malignant melanoma. One such an advance is the treatment with BRAF tyrosine-kinase inhibitors in metastatic malignant melanomas that harbor mutations in the BRAF gene. The trials that have been performed in this setting have demonstrated superior response rates and increased overall survival, however they mostly included patients with melanomas carrying the more common V600E and V600K mutations, not being able to assess the benefit of these treatm...

Targeted inhibition of the BRAF pathway in a patient with stage IV melanoma.

This article describes the use of vemurafenib, a BRAF inhibitor, to achieve disease regression in a woman with extensive metastatic melanoma and the BRAF V600 gene mutation. Given the improved survival rates seen in these patients, clinicians need to be aware of long-term patient management and adverse reactions to the drug.

BRAF V600E mutation is a significant prognosticator of the tumour regrowth rate in brainstem gangliogliomas.

BRAF V600E mutations are progression factors in paediatric low-grade gliomas. Furthermore, a high percentage of paediatric brainstem gangliogliomas have BRAF V600E mutations. However, their clinical significance, including possible connections between the biomarkers and ganglioglioma's clinical features, especially a brainstem counterpart, is unclear. To identify potential molecular features predictive of brainstem ganglioglioma's clinical outcomes, a retrospective cohort of 28 World Health Organization (WH...

MAPK pathway inhibitors rescue lethal phenotypes in a BRAF gain-of-function Drosophila melanogaster model.

Mutant BRAF is the leading oncogene in melanoma and is found in close to 50% of all melanoma patients (Cancer_Genome_Atlas_Network, 2015). The oncogenic capacity of the BRAFV600E mutation has also been demonstrated in a murine melanoma model (Dankort et al., 2009). This mutation causes the activation of the mitogen-activated protein kinase (MAPK) pathway, which involves BRAF kinase and downstream mitogen-activated extracellular signal-regulated kinases 1/2 (MEK1/2) and extracellular signal-regulated kinase...

Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.

BRAF and NRAS mutations arise early in melanoma development but their associations with low-penetrance melanoma susceptibility loci remain unknown. In the Genes, Environment and Melanoma (GEM) Study, 1223 European-origin participants had their incident invasive primary melanomas screened for BRAF/NRAS mutations and germline DNA genotyped for 47 single-nucleotide polymorphisms (SNPs) identified as low-penetrant melanoma risk variants. We used multinomial logistic regression to simultaneously examine each SNP...

The Significance of TROP2 Expression in Predicting BRAF Mutations in Papillary Thyroid Carcinoma.

Trophoblast antigen 2 (TROP2) is a human trophoblast cell-surface glycoprotein that is overexpressed in several types of epithelial cancers, and is suggested to be associated with an unfavorable prognosis. BRAF mutations are the most common genetic alteration in papillary thyroid carcinoma (PTC). We evaluated the correlation between TROP2 expression and BRAF mutation in PTC.

BRAF ANTIBODY EXPRESSION IN DIFFERENT TYPES OF THYROID NODULAR LESIONS.

Major problems haunt the physicians who need to delineate the best management strategy for their patients with thyroid nodule is the identification of the most aggressive cases, especially among papillary thyroid cancers, which would benefit from more aggressive therapy and follow up. Beyond its strong correlation with PTC, the BRAF mutation is well described to associate with poor prognosis. The aim of our study was to identify BRAF antibody expression in different hystotypes of the thyroid nodules and ass...

First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.

Colorectal carcinomas (CRCs) are sensitive to treatment by anti-epidermal growth factor receptor (EGFR) antibodies only if they do not carry activating mutations in down-stream EGFR targets (KRAS/NRAS/BRAF). Most clinical trials for chemo-naive CRC patients involved combination of targeted agents and chemotherapy, while single-agent cetuximab or panitumumab studies included either heavily pretreated patients or subjects who were not selected on the basis of molecular tests. We hypothesized that anti-EGFR th...

Thoracic involvement in Erdheim-Chester disease: computed tomography imaging findings and their association with the BRAF mutation.

To investigate the computed tomography (CT) thoracic findings in Erdheim-Chester disease (ECD) and evaluate the association of these findings with the BRAF mutation.

Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.

Activating mutations in RAS genes are associated with approximately 20% of all human cancers. New targeted therapies show preclinical promise in inhibiting the KRAS G12C variant. However, concerns exist regarding the effectiveness of such therapies in vivo given the possibilities of existing intratumor heterogeneity or de novo mutation leading to treatment resistance. We performed deep sequencing of 27 KRAS G12-positive lung tumors to determine the prevalence of other oncogenic mutations within KRAS or with...


Advertisement
Quick Search
Advertisement
Advertisement